BRIEF published on 07/28/2025 at 19:46, 4 months 7 days ago SUSS MicroTec Adjusts 2025 Financial Guidance Financial Guidance EBIT Margin Gross Profit Margin Sales Target 2025 Forecast
PRESS RELEASE published on 07/28/2025 at 19:41, 4 months 7 days ago EQS-Adhoc: SUSS adjusts its guidance for gross profit margin and EBIT margin in financial year 2025 SUSS MicroTec SE adjusts 2025 guidance for gross profit margin and EBIT margin based on preliminary figures and ongoing analysis Financial Analysis Preliminary Figures SÜSS MicroTec SE Guidance Adjustment 2025 Forecast
BRIEF published on 06/04/2025 at 10:35, 6 months ago SUSS MicroTec SE AGM Approves 50% Dividend Increase and Re-Elects Jan Smits Shareholder Approval Dividend Increase Company Growth 2025 Outlook Jan Smits Re-Election
PRESS RELEASE published on 06/04/2025 at 10:30, 6 months ago Annual General Meeting approves dividend proposal and re-elects Jan Smits to the Supervisory Board SUSS MicroTec SE's Annual General Meeting approves 50% dividend increase to € 0.30 per share, re-elects Jan Smits to Supervisory Board, and presents growth plans for 2025 Supervisory Board Dividend Increase SÜSS MicroTec SE Jan Smits 2025 Growth Plans
BRIEF published on 05/26/2025 at 08:05, 6 months 9 days ago SUSS MicroTec Launches XBC300 Gen2 D2W Hybrid Bonding Platform SÜSS MicroTec Semiconductor Hybrid Bonding Die-to-wafer Bonding 3D IC Technologies
PRESS RELEASE published on 05/26/2025 at 08:00, 6 months 10 days ago SUSS presents the XBC300 Gen2 D2W platform – the integrated and precise solution for the future of die-to-wafer hybrid bonding SUSS introduces the XBC300 Gen2 D2W platform, offering high precision and space savings for die-to-wafer hybrid bonding in semiconductor manufacturing Semiconductor Industry Precision Hybrid Bonding SUSS XBC300 Gen2 D2W Platform
BRIEF published on 05/08/2025 at 07:35, 6 months 28 days ago SUSS MicroTec Reports Strong Sales Growth in Q1 2025 Sales Growth SÜSS MicroTec Semiconductor Q1 2025 Tariff Risks
PRESS RELEASE published on 05/08/2025 at 07:30, 6 months 28 days ago SUSS continues high sales growth in the first quarter of 2025 SUSS MicroTec SE reports 31.8% sales growth in Q1 2025, with margins and guidance confirmed. Key driver: bonder orders related to AI. Expansion plans in Taiwan progressing as planned Sales Growth SÜSS MicroTec SE Quarterly Statement Taiwan Expansion AI Bonder Orders
BRIEF published on 03/27/2025 at 07:35, 8 months 9 days ago SUSS MicroTec Targets Growth in 2025 Financial Year Sales Growth Dividend Increase Financial Outlook Semiconductor Profit Margin
PRESS RELEASE published on 03/27/2025 at 07:30, 8 months 9 days ago SUSS is aiming for further sales growth in the 2025 financial year SUSS MicroTec SE aims for sales growth in 2025 financial year, with sales expectation of €470-510 million, gross profit margin guidance of 39-41%, and EBIT margin of 15-17% Sales Growth Annual Report Forecast SÜSS MicroTec SE 2025 Financial Year
Published on 12/05/2025 at 02:35, 5 hours 28 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 7 hours 3 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 58 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 3 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 1 hour 3 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 33 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 8 hours 12 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 38 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 48 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 14 hours 3 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 18 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 19 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 14 hours ago Declaration of voting rights at the end of November 2025
